|Bid||388.52 x 800|
|Ask||387.91 x 1000|
|Day's range||381.29 - 389.67|
|52-week range||312.33 - 449.38|
|Beta (5Y monthly)||1.19|
|PE ratio (TTM)||52.30|
|Earnings date||27 Oct 2021 - 01 Nov 2021|
|Forward dividend & yield||1.36 (0.35%)|
|Ex-dividend date||13 Aug 2021|
|1y target est||462.55|
Teleflex (NYSE:TFX) has had a rough three months with its share price down 5.2%. However, stock prices are usually...
Late-Breaking Data Presentation Reveals How UroLift PUL’s Post-Operative Events Compare With Other Minimally Invasive Procedures and Traditional Surgery for the Treatment of BPHWAYNE, Pa., Sept. 14, 2021 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE:TFX) today announced that new real-world healthcare claims data reveal that the risk of return procedures is lowest after treatment with the UroLift® System among the analyzed benign prostatic hyperplasia (BPH) treatment options. The data also show
Teleflex's (TFX) new real-world data outcomes together with product launches demonstrate the importance of UroLift System for most BPH patients.